Related Experiment Video
Updated: Aug 30, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time
Douglas B Wilhite1, Anthony J Comerota, Frank A Schmieder
1Department of Surgery, University Hospital, Temple University School of Medicine, Philadelphia, PA, USA.
Insights
Platelet inhibitors aspirin and clopidogrel prolong bleeding time in peripheral arterial disease (PAD) patients, especially in combination. Cilostazol does not further increase bleeding time when added to these therapies.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hematology
Background:
- Peripheral arterial disease (PAD) significantly increases cardiovascular risks.
- Platelet inhibition (PI) is crucial for reducing these risks in PAD patients.
- Combination PI is common, but its effect on platelet function requires objective evaluation.
Purpose of the Study:
- To evaluate the effect of commonly used platelet inhibitors (aspirin, clopidogrel, cilostazol) singly and in combination on platelet function in PAD patients.
- To assess the impact of these agents on bleeding time (BT) as a measure of platelet function.
Main Methods:
- A prospective, sequential study involving 21 PAD patients.
- Patients underwent two-week regimens of various platelet inhibition therapies, including washout periods.
- Bleeding time was measured after each treatment phase.
Main Results:
- Aspirin and clopidogrel significantly prolonged bleeding time individually (P < 0.01).
- Combination therapy with aspirin and clopidogrel showed a more pronounced prolongation of bleeding time compared to monotherapy (P < 0.01).
- Cilostazol alone did not significantly affect bleeding time, nor did its addition to aspirin, clopidogrel, or their combination.
Conclusions:
- Aspirin and clopidogrel are effective platelet inhibitors for PAD patients, significantly increasing bleeding time, particularly when combined.
- Cilostazol, used for intermittent claudication, can be safely co-administered with aspirin and/or clopidogrel without an additional impact on bleeding time.
- The findings support the use of cilostazol in combination therapy for PAD patients without increasing bleeding risk.
Purpose:
Patients with lower-extremity peripheral arterial disease (PAD) face a high risk of cardiovascular morbidity and mortality. Platelet inhibition (PI) significantly reduces this risk. Combination PI is common and increasingly indicated in patients with PAD; however, the effect on platelet function has not been objectively evaluated. Aspirin (ASA), clopidogrel (Clop), and cilostazol (Cilo) are the three most commonly used PI drugs in patients with PAD. A prospective, sequential evaluation of platelet function using the template bleeding time (BT) was performed for PAD patients taking these medications singly and in combination.
Methods:
Twenty-one patients with PAD, averaging 65.9 years of age, were studied. Patients were placed on sequential two-week regimens of the following therapies: washout (no PI), ASA (325 mg daily), ASA + Cilo (100 mg twice daily), washout, Cilo, Cilo + Clop (75 mg each day), washout, Clop, Clop + ASA, and Clop + ASA + Cilo. At the end of each phase, trained personnel measured the BT.
Results:
Baseline bleeding time for the group was 4.29 +/- 1.69 minutes. ASA (BT = 6.64 +/- 3.52) and Clop (BT = 10.17 +/- 5.4) significantly prolonged bleeding time (P < 0.01); however, no significant effect was observed with Cilo alone (BT = 5.41 +/- 2.69). Combined treatment with ASA + Clop (BT = 17.39 +/- 4.59) had a more pronounced effect on BT compared with either agent alone (P < 0.01). The addition of Cilo to either ASA (BT = 8.3 +/- 4.27) or Clop (BT = 12.7 +/- 7.46) or the combination of ASA + Clop (BT = 17.92 +/- 4.69) did not prolong BT.
Conclusion:
All patients with PAD require platelet inhibition, and many require pharmacotherapy for intermittent claudication. The platelet inhibitors aspirin and clopidogrel are used for the reduction of ischemic events. They significantly prolong bleeding time individually and to a greater extent in combination. Cilo is used to improve walking distance in patients with intermittent claudication. When Cilo is added to ASA, Clop, or the combination of the two, there is no additional increase in bleeding time. Therefore, Cilo can be used in combination with other platelet inhibitors without an additional effect on platelet function as reflected by the bleeding time.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:27Peripheral Artery Disease III: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care
01:30Drug toxicity: Drug–Drug Interaction